Mölnlycke at a glance
A world-leading MedTech company
Mölnlycke has been at the forefront of change since 1849, pioneering radical innovation that improves the quality of life for patients and those who care for them, while reducing the environmental impact of healthcare. We provide effective solutions and we’re always on the lookout for new ways to improve.
-
Our purpose
Our purpose is to revolutionise care for people and planet. We drive change that improves the health and wellbeing of patients and those who care for them – while reducing the environmental footprint of healthcare.
Read more about our purpose -
Our strategy
Mölnlycke aims to become the market leader across all segments and geographies where the company operates. This ambition is firmly grounded in a strong portfolio of brands, as well as strong heritage of customer-insight driven innovations that improve the lives of people and planet.
Read more about our strategy
We care about sustainability
Sustainability is a strategic priority at Mölnlycke and WeCare is our sustainability roadmap for 2030. It means creating shared value for all our stakeholders. It is a driver for growth, innovation and productivity and an essential part of our employee value proposition.
How we work with sustainabilityLatest news
-
Mölnlycke improves overall score in 2026 EcoVadis sustainability assessment
Mölnlycke has further strengthened its sustainability performance in the latest EcoVadis assessment, achieving a ranking in the 98th percentile.
-
Dartford and Gravesham NHS Trust adopts Steriwave to support infection prevention
Dartford and Gravesham NHS Trust in the UK has adopted Steriwave® nasal photodisinfection for elective orthopaedic surgery, working with Mölnlycke and Ondine Biomedical to strengthen its approach to surgical site infection prevention.
-
New leaders appointed for Mölnlycke Health Care
Gothenburg, Sweden. 3 November 2026. Mölnlycke® announces the appointment of Anders Andersson as Chief Executive Officer (CEO) of Mölnlycke Health Care and Fredrik Wallefors as President of Surgical, effective 1 January 2027.
-
Mölnlycke Health Care announces new partnership with DEBRA International to help advance wound care for the EB community
Mölnlycke is partnering with DEBRA International, the world’s leading epidermolysis bullosa (EB) patient advocacy network, to deepen understanding of the needs of people living with EB and help advance wound care for the global EB community.
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold strategic partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.